Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Millions of stroke survivors across the world may soon have a new defense
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Subscribe To Our Newsletter & Stay Updated